← Eichor
Study identifier: NCT04678258 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation

Condition: Catheter Ablation · Atrial Flutter Typical · Radiation Exposure  ·  Sponsor: Klinikum-Fuerth

PhaseNA
Planned participants106
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Catheter ablation of the cavo-tricuspid isthmus (CTI) is the curative first-line therapy for typical atrial flutter. Currently, two approaches are used in clinical practice. In contrast to the conventional linear ablation approach, the Maximum voltage-guided (MVG) strategy aims to limit ablation to high voltage areas (HVAs) representing the detectable correlate of relevant conducting bundles. Data from registries show that the MVG technique is sufficient to reach comparable clinical outcome with significantly shorter ablation duration when compared to the conventional linear strategy. Despite growing evidence, however, data from properly powered prospective randomized trials are lacking and the linear approach still remains standard. In addition, data on radiation exposure are controversial. As a substrate-based approach, the MVG strategy requires detailed mapping and signal analysis for identification of the individual architecture and exactly targeted energy application. However, the spatial mapping resolution of large tip catheters is limited. The use of the MicroFidelity catheter technology (IntellaMiFi) with high resolution mini-electrodes at the 8 mm catheter tip can be expected to further improve the feasibility of a voltage-guided approach. In addition, the MVG approach theoretically may encompass an increased risk for clinically inapparent reconduction. A prospective study with predefined invasive re-evaluation of persistent CTI block is needed to further evaluate …

This description comes directly from the study's public registry record.

Talk to the study team

Dirk Bastian, MD  ·  7580 1101  ·  dirk.bastian@klinikum-fuerth.de

Laura Vitali-Serdoz, MD  ·  7580 1101  ·  laura.vitali-serdoz@klinikum-fuerth.de

Always discuss trial participation with your own doctor first.

Locations (1)

Klinikum FuerthFürth, Bavaria, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04678258